These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 10952298)

  • 1. Oncogene inactivation in a mouse model.
    Tanabe T; Kuwabara T; Warashina M; Tani K; Taira K; Asano S
    Nature; 2000 Aug; 406(6795):473-4. PubMed ID: 10952298
    [No Abstract]   [Full Text] [Related]  

  • 2. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
    Mendoza-Maldonado R; Zentilin L; Fanin R; Giacca M
    Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ribozyme mediated therapy for chronic myelogenous leukemia.
    Leopold LH; Shore SK; Newkirk T; Mangan K; Reddy EP
    Prog Clin Biol Res; 1994; 389():175-82. PubMed ID: 7700900
    [No Abstract]   [Full Text] [Related]  

  • 4. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribozyme-mediated cleavage of the BCRABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity.
    Shore SK; Nabissa PM; Reddy EP
    Oncogene; 1993 Nov; 8(11):3183-8. PubMed ID: 8414522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
    Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
    Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligodeoxynucleotides for the treatment of chronic myelogenous leukemia: are they still a promise?
    de Fabritiis P; Calabretta B
    Haematologica; 1995; 80(4):295-9. PubMed ID: 7590496
    [No Abstract]   [Full Text] [Related]  

  • 8. Oligonucleotide therapeutics: clothing the emperor.
    Gewirtz AM
    Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allosterically controllable maxizyme-mediated suppression of progression of leukemia in mice.
    Kuwabara T; Tanabe T; Warashina M; Xiong KX; Tani K; Taira K; Asano S
    Biomacromolecules; 2001; 2(4):1220-8. PubMed ID: 11777396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An intron promotes the anti-bcr-abl activities of a retrovirally expressed ribozyme in chronic myeloid leukemia cells.
    Liu JH; Wu SC; Chen WS; Yen CC; Yang MH; Tsai YC; Chen PM
    Biochem Biophys Res Commun; 2004 Jun; 318(3):764-72. PubMed ID: 15144904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
    Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
    Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stable RNA interference (RNAi) as an option for anti-bcr-abl therapy.
    Scherr M; Battmer K; Schultheis B; Ganser A; Eder M
    Gene Ther; 2005 Jan; 12(1):12-21. PubMed ID: 15602589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic gene therapy of myeloproliferative disease developed in transgenic mice expressing P230 bcr/abl.
    Miyake K; Inokuchi K; Miyake N; Dan K; Shimada T
    Gene Ther; 2005 Mar; 12(6):541-5. PubMed ID: 15616602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model mice for BCR/ABL-positive leukemias.
    Honda H; Hirai H
    Blood Cells Mol Dis; 2001; 27(1):265-78. PubMed ID: 11358387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific bcr-abl-directed antisense nucleic acids and ribozymes: a tool for the treatment of chronic myelogenous leukemia?
    Kronenwett R; Haas R
    Recent Results Cancer Res; 1998; 144():127-38. PubMed ID: 9304714
    [No Abstract]   [Full Text] [Related]  

  • 16. Multi-unit anti-BCR-ABL ribozyme therapy in chronic myelogenous leukemia.
    Leopold LH; Shore SK; Reddy EP
    Leuk Lymphoma; 1996 Aug; 22(5-6):365-73. PubMed ID: 8882949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW; Ren R
    Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector.
    Sengupta A; Banerjee D; Chandra S; Banerjee S
    J Gene Med; 2006 Oct; 8(10):1251-61. PubMed ID: 16952195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging].
    Wu Y; Chen YZ; Huang HF; Chen P; Lu LH
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep; 35(9):859-63. PubMed ID: 12958661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells.
    Nimmanapalli R; Bali P; O'Bryan E; Fuino L; Guo F; Wu J; Houghton P; Bhalla K
    Cancer Res; 2003 Nov; 63(22):7950-8. PubMed ID: 14633726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.